OTCMKTS:QBIO Q BioMed (QBIO) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free QBIO Stock Alerts $0.0002 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0155VolumeN/AAverage Volume538 shsMarket Capitalization$29,020.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsStock AnalysisChartEarningsFinancialsSEC Filings Get Q BioMed alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Q BioMed Stock (OTCMKTS:QBIO)Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.Read More QBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QBIO Stock News HeadlinesMarch 11, 2024 | msn.comClearside Biomedical Q4 2023 Earnings PreviewFebruary 24, 2024 | benzinga.comQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 13, 2024 | msn.comBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesJanuary 28, 2024 | msn.comBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthNovember 16, 2023 | morningstar.comQ BioMed Inc QBIOAugust 18, 2023 | seekingalpha.comQBIO Q BioMed Inc.April 14, 2023 | proactiveinvestors.comQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 14, 2023 | finance.yahoo.comQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for EuropeMarch 3, 2023 | benzinga.comQ BioMed Stock (OTC:QBIO), Quotes and News SummaryFebruary 10, 2023 | proactiveinvestors.comQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside BFebruary 10, 2023 | finance.yahoo.comQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent OfficeJanuary 12, 2023 | benzinga.comShort Volatility Alert: Q Biomed IncJanuary 1, 2023 | finance.yahoo.comQ BioMed Inc. (QBIO)November 14, 2022 | proactiveinvestors.comQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin ResearchNovember 14, 2022 | finance.yahoo.comQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.October 11, 2022 | prnewswire.comQ BIOMED PROVIDES SHAREHOLDER UPDATESeptember 27, 2022 | proactiveinvestors.comQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentSeptember 27, 2022 | finance.yahoo.comQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERAugust 25, 2022 | finance.yahoo.comTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.July 29, 2022 | finance.yahoo.comQ BioMed Inc. Provides Update to ShareholdersJuly 26, 2022 | proactiveinvestors.comQ BioMed welcomes study that highlights the safety and efficacy of Uttroside-B chemotherapeuticJuly 26, 2022 | finance.yahoo.comQ BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancerMay 11, 2022 | investing.comQ BioMed Inc (QBIO)May 6, 2022 | proactiveinvestors.comQ BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar marketsMay 6, 2022 | finance.yahoo.comQ BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar MarketsSee More Headlines Receive QBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/14/2021Today4/23/2024Next Earnings (Estimated)5/26/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:QBIO Previous SymbolNASDAQ:QBIO CUSIPN/A CIK1596062 Webwww.qbiomed.com Phone(646) 889-2226FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$280,000.00 Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book0.00Miscellaneous Outstanding Shares145,100,000Free Float104,178,000Market Cap$29,020.00 OptionableNot Optionable Beta1.71 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Denis D. Corin (Age 51)Chairman, CEO & President Comp: $300kMr. William S. Rosenstadt (Age 56)Chief Legal Officer, General Counsel & Director Comp: $300kKey CompetitorsBohai Pharmaceuticals GroupOTCMKTS:BOPHNVN LiquidationNASDAQ:NOVNQImagenetixOTCMKTS:IAGXEndonovo TherapeuticsOTCMKTS:ENDVDSophiris BioOTCMKTS:SPHSView All Competitors QBIO Stock Analysis - Frequently Asked Questions How have QBIO shares performed in 2024? Q BioMed's stock was trading at $0.0004 on January 1st, 2024. Since then, QBIO shares have decreased by 50.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. When is Q BioMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Sunday, May 26th 2024. View our QBIO earnings forecast. How were Q BioMed's earnings last quarter? Q BioMed Inc. (OTCMKTS:QBIO) issued its quarterly earnings data on Wednesday, July, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. The business earned $0.05 million during the quarter. What other stocks do shareholders of Q BioMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T). How do I buy shares of Q BioMed? Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:QBIO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest MetalsThe only defense company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q BioMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
